heyOn Thursday, Simon Loput’s two-year-old daughter Jane became ill with fever. As soon as possible the young father and his wife rushed to a nearby hospital in Uganda’s northern Nbilatuk district, where their worst fears were confirmed: their child had malaria. Simon’s ability to react quickly came from experience, the mosquito-borne disease that has plagued his community for generations.
“My daughter is improving now but it is still appalling. Our hospitals are not very comfortable as there is very less space in the wards.” Granthshala via video call. “It’s also troublesome in terms of money because sometimes the medicines in the hospital are not enough, so I have to spend a lot to buy the medicines my daughter needs.”
The day before the tragedy on the Loput family, the World Health Organization (WHO) Rollout approved World’s first malaria vaccine with moderate to high levels of transmission in sub-Saharan Africa and other regions. The vaccine, known as RTS, S, or Mosquirix, was developed by GlaxoSmithKline (GSK), a British pharmaceutical company Headquarters in London. for development over 30 years, rts, is the efficacy of s low at 39% and only works against P. falciparum The most dangerous malaria parasite globally. Nevertheless, it is an important step towards eradicating a disease that causes over 409,000 deaths In 2019, most of whom were children below five years of age.
Credit: www.independent.co.uk /